Additional file 4: of Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
Xiaotong Li
Sarah Warren
Vasiliki Pelekanou
Vikram Wali
Alessandra Cesano
Mingdong Liu
Patrick Danaher
Nathane Elliott
Zeina Nahleh
Daniel Hayes
Gabriel Hortobagyi
William Barlow
Christos Hatzis
Lajos Pusztai
10.6084/m9.figshare.7975223.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_4_of_Immune_profiling_of_pre-_and_post-treatment_breast_cancer_tissues_from_the_SWOG_S0800_neoadjuvant_trial/7975223
Figure S4. Correlation between TIL counts and PD-L1 expression. A. Correlation between TIL counts and PD-L1 expression on tumor cells. B. Correlation between TIL counts and PD-L1 expression on stromal cells. C. TIL counts in cases with positive and negative PD-L1 expression on tumor cells. D. TIL counts in cases with positive and negative PD-L1 expression on stromal cells. For A and B, Solid line and grey shade represent linear regression line and 95% confidence interval, respectively. Besides, Pearson correlation coefficient r and p-value are added. For C and D, p values are from Wilcoxon test. (PDF 74 kb)
2019-04-10 05:00:00
Tumor infiltrating lymphocytes
PD-L1
Immune-related genes
Neoadjuvant treatment
Bevacizumab